Cell lines and methods for producing recombinant adeno-associated virus
AssigneeRegents of the University of Minnesota
InventorsMin Lu, Zion Lee, Wei-Shou Hu, Han-Jung Kuo, Yu-Chieh Lin
Life of this patent
Estimating the term…
Abstract
A stable mammalian cell line includes a first polynucleotide encoding a first AAV inverted terminal repeat (ITR) sequence. In one or more embodiments, the first polynucleotide includes a first inducible promoter. The stable mammalian cell line may further include a second polynucleotide encoding a repressor, wherein the first inducible promoter is operably linked to the repressor. A method of using a stable mammalian cell line includes contacting the stable mammalian cell line with an inducer. A polynucleotide encodes a first AAV inverted terminal repeat (ITR) sequence, a first inducible promoter, and a repressor.
Claims34
A stable mammalian cell line comprising:
- a first polynucleotide encoding a first AAV inverted terminal repeat (ITR) sequence, a second ITR sequence, and a first promoter, wherein the first promoter is not expressed in the stable mammalian cell line and wherein the first promoter is a tissue-specific promoter or a first inducible promoter.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
14-24. (canceled)
A stable mammalian cell line, comprising:
- a first polynucleotide encoding an AAV large replicate (Rep) protein, wherein the first polynucleotide is operably linked to a first inducible promoter;
- a second polynucleotide encoding an adenovirus (Ad) E4orf6, wherein the second polynucleotide is operably linked to a second inducible promoter;
- a third polynucleotide encoding an Ad DNA binding protein (DBP), wherein the third polynucleotide is operably linked to a third inducible promoter;
- a fourth polynucleotide encoding an AAV capsid protein, wherein the fourth polynucleotide is operably linked to a fourth inducible promoter;
- and
- a fifth polynucleotide encoding an AAV small Rep protein, wherein the fifth polynucleotide is operably linked to a fifth inducible promoter.
27-30. (canceled)
35-37. (canceled)
40-43. (canceled)
45-53. (canceled)
55-57. (canceled)
59-65. (canceled)
Dependencies are inferred from the claim text.